TWO-PHASE DYNAMICS OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS (MMSC) ACTION ON LIVER AT MODELING OF FIBROTIC HEPATITIS
https://doi.org/10.15825/1995-1191-2011-3-51-58
Abstract
Under the modeling of chronic fibrousing hepatitis in rats (n = 75) the dynamics of fibrolytic effect of bone mar- row MMSC was examined after one or two-time infusion of these cells at the early stage of liver fibrosis. By dynamic measuring of liver fibrotic area and the expression of activated stellate cell markers (desmin, α-SMA) and markers of cell apoptosis (caspase-3 and caspase-9) within 90 days two phases of the development of bone marrow MMSC fibrolytic effect were found.
It is shown that the development of fibrolytic effect includes the primary phase of intensification of fibrosis, which is followed by the phase of enhanced fibrolytic process in the liver. It was determined that the two-phase dynamics of liver regeneration was more intensive after two-time infusion of bone marrow MMSC.
About the Authors
N. A. Onishchenko
Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
A. V. Lyundup
Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
I. M. Gazizov
Kazan State Medical University, Kazan
Russian Federation
Russian Federation
R. V. Deev
Human Stem Cells Institute, Moscow
Russian Federation
Russian Federation
M. Y. Shagidulin
Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
М. Е. Krasheninnikov
Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
P. V. Avramov
Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Federation
Russian Federation
References
1. Гумерова А.А., Киясов А.П. Могут ли перисинусои- дальные клетки быть региональными стволовыми (прогениторными) клетками печени? // Клеточная трансплантология и тканевая инженерия. 2010. Т. 5 (1). С. 33–40.
2. Aziz M.T.A., Atta H.M., Mahfouz S. et al. Therapeutic po- tential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis // Clin. Biochem. 2007. Vol. 40. P. 893–899.
3. Bonzo L.V., Ferrero I., Cravanzola C. et al. Human me- senchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte dif- ferentiation versus profibrogenic potential // Gut. 2008. Vol. 57. P. 223–231.
4. Dai L.J, Li H.Y. et al. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cir- rhosis // Stem. Cell Res. 2009. Vol. 2 (1). P. 16–25.
5. Dalakas E., Newsome P.N., Boyle S. et al. Bone marrow stem cells contribute to alcohol liver fibrosis in humans // Stem. Cells Dev. 2010 Sep. Vol. 19 (9). P. 1417–1425.
6. Dugast A., Vanhove B. Immune regulation by non-lym- phoid cells in transplantation // Clin. Exp. Immunol. 2009 April. Vol. 156 (1). P. 25–34.
7. Friedman S.L. Reversibility of hepatic fibrosis and cir- rhosis – is it all hype? // Nat. Clin. Pract. Gastroenterol. Hepatol. 2007. Vol. 4. P. 236–237.
8. Friedman S.L. Hepatic stellate cells: protean, multifunc- tional, and enigmatic cells of the liver // Physiol. Rev. 2008. Vol. 88. P. 125–172.
9. Higashiyama R., Inagaki Y., Hong Y.Y. et al. Bone mar- row-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice // Hepa- tology. 2007. Vol. 45. P. 213–222.
10. Higashiyama R., Moro T., Nakao S. et al. Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice // Gastro- enterology. 2009 Oct. Vol. 137 (4). P. 1459–1466.
11. Kordes C., Sawitza I., Müller-Marbach A. et al. CD133+ hepatic stellate cells are progenitor cells // Biochem. Bio- phys. Res. Commun. 2007 Jan 12. Vol. 352 (2). 417 p.
12. Kuo T.K., Hung S. et al. Stem cell therapy for liver dis- ease: parameters governing the success for using bone marrow mesenchymal stem cells // Gastroenterology. 2008. Vol. 134. P. 2111–2121.
13. Parekkadan B., Poll D., Suganuma K. et al. Mesenchy- mal stem cell-derived molecules reverse fulmimant he- patic failure // PLoS One. 2007. Vol. 2 (9). Р. e941.
14. ParolaM.,MarraF.,PinzaniM.Myofibroblast-likecells and liver fibrogenesis: emerging concepts in a rapidly moving scenario // Mol. Aspects. Med. 2008. Vol. 29. P. 58–66.
15. Poll D., Parekkadan B., Cho C.H. et al. Mesenchymal stem cellderived molecules directly modulate hepatocel- lular death and regeneration in vitro and in vivo // Hepa- tology. 2008. Vol. 47. P. 1634–1643.
16. Povero D., Busletta C., Novo E. et. al. Liver fibrosis: a dynamic and potentially reversible process // Histol. His- topathol. 2010 Aug. Vol. 25 (8). P. 1075–1091.
17. RussoF.P.,AlisonM.R.,BiggerB.W.etal.Thebonemar- row functionally contributes to liver fibrosis // Gastroen- terology. 2006. Vol. 130. P. 1807–1821.
18. Sakaida I., Terai S., Yamamoto N. et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice // Hepatology. 2004. Vol. 40. P. 1304–1311.
19. Yagi H., Soto-Gutierrez A., Navarro-Alvarez N. et al. Re- active bone marrow stromal cells attenuate systemic in- flammation via sTNFR1 // Mol. Ther. 2010 Oct. Vol. 18 (10). P. 1857–1864.
20. Yu Y., Yao A.H., Chen N. et al. Mesenchymal stem cells over-expressing hepatocyte growth factor improve small-for-size liver grafts regeneration // Mol. Ther. 2007. Vol. 15. P. 1382–1389.
Review
For citations:
Onishchenko N.A., Lyundup A.V., Gazizov I.M., Deev R.V., Shagidulin M.Y., Krasheninnikov М.Е., Avramov P.V. TWO-PHASE DYNAMICS OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS (MMSC) ACTION ON LIVER AT MODELING OF FIBROTIC HEPATITIS. Russian Journal of Transplantology and Artificial Organs. 2011;13(3):51-58. (In Russ.) https://doi.org/10.15825/1995-1191-2011-3-51-58
Views:
826
Email this article 